Interferon gamma News and Research

RSS
SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

SARS-CoV-2 Omicron found to be more immune evasive than other variants among mild COVID-19 convalescent patients

In-depth characterization of the BA.2 versus BA.1 variant

In-depth characterization of the BA.2 versus BA.1 variant

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

A study of SARS-CoV-2-mRNA booster vaccinations in immunocompromised patients

Exploring age-associated differences in T lymphocyte immune responses after BNT162b2 vaccination

Exploring age-associated differences in T lymphocyte immune responses after BNT162b2 vaccination

Study investigates the cause of lymphopenia as seen in COVID-19 patients

Study investigates the cause of lymphopenia as seen in COVID-19 patients

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Study assesses the efficacy and safety of lithium treatment in patients infected with severe SARS-CoV-2

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

Long COVID is characterized SARS-CoV-2 antigen persistence in the gut mucosa

Novel wearable sensor can detect two key biomarkers of infection in sweat

Novel wearable sensor can detect two key biomarkers of infection in sweat

Safety and immunogenicity of three-dose vaccination with the Pfizer/BioNtech SARS-CoV-2 mRNA vaccine

Safety and immunogenicity of three-dose vaccination with the Pfizer/BioNtech SARS-CoV-2 mRNA vaccine

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

Chimeric Delta-Omicron RBD-dimer vaccine found to be effective against SARS-CoV-2 variants

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Study demonstrates that a low-dose, bivalent, unmodified mRNA vaccine against SARS-CoV-2 is highly efficacious

Study demonstrates subset of vaccine-induced HLA-A*24:02-restricted T cells exhibits enhanced reactivity against the Omicron BA.1 variant

Study demonstrates subset of vaccine-induced HLA-A*24:02-restricted T cells exhibits enhanced reactivity against the Omicron BA.1 variant

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

Treg cell Notch receptors drive SARS-CoV-2-induced MIS-C

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

mRNA vaccines induce CD8+ T cells that may reduce COVID-19 severity

SARS-CoV-2 mutations change proteasome processing to alter CD8+ T cell responses

SARS-CoV-2 mutations change proteasome processing to alter CD8+ T cell responses

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

Study characterizes SARS-CoV-2 spike-specific cluster of differentiation 4+ T-cell response

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.